
Essais actifs
Ces essais cliniques sur la COVID-19 sont actifs et approuvés par Santé Canada. Beaucoup d’autres sont en attente d’approbation et seront ajoutés dans les jours et les semaines à venir.
Aidez-nous à fermer la boucle. Ajoutez votre essai à notre liste d’essais cliniques canadiens actifs sur la COVID-19 et accédez à un registre des participants élargi.


















The study uses an adaptive design with initial enrolment in the Ambulatory cohort (Cohort A) followed by a safety assessment before initiation of enrolment in the Hospitalized cohort (Cohort B). Ambulatory patients (Cohort A) with confirmed COVID-19 deemed well enough for home isolation will be randomized to receive a single subcutaneous injection of Peginterferon lambda 180µg prior to discharge or no therapy. Patients will be followed remotely with a home visit for a repeat swab at Day 4 and 8 with the primary endpoint being the proportion positive for SARS-CoV-2 on Day 8. Safety data will be reviewed by the Data Safety and Monitoring Committee after 50% of the Ambulatory cohort (n=60) has been enrolled. If the committee approves study continuation, enrolment will continue in the Ambulatory cohort (Cohort A) and will begin in the Hospitalized cohort (Cohort B). Hospitalized patients (Cohort B) with moderate but not severe COVID-19 will be enrolled and randomized to Peginterferon lambda 180µg on Day 1 and 8, or best supportive care. The primary endpoint will be the proportion positive for SARS-CoV-2 by nasopharyngeal swab on Day 15. In addition to the primary endpoints on which the study is powered, numerous secondary endpoints will be evaluated. Samples will also be collected for ancillary studies to better understand predictors of disease severity and response to treatment.







Le program de recherches ACT COVID-19 constitue deux études parallèles comparant le traitement, communautaire ou hospitalier, avec l'azithromycine et la chloroquine au soins standards, pour des patients testé positif pour le COVID-19





Phase 2: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19 Phase 3: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19